Bill Status of SB 66   104th General Assembly

Short Description:  HEALTH CARE AVAILABILITY

Senate Sponsors
Sen. Robert Peters, Michael W. Halpin, Mary Edly-Allen, Rachel Ventura, Mike Porfirio-David Koehler, Laura M. Murphy-Mike Simmons-Karina Villa-Graciela Guzmán, Christopher Belt, Celina Villanueva, Mark L. Walker, Kimberly A. Lightford and Doris Turner

Last Action  View All Actions

DateChamber Action
  1/13/2025SenateReferred to Assignments

Statutes Amended In Order of Appearance
New Act
30 ILCS 105/5.1030 new

Synopsis As Introduced
Creates the Health Care Availability and Access Board Act. Establishes the Health Care Availability and Access Board to protect State residents, State and local governments, commercial health plans, health care providers, pharmacies licensed in the State, and other stakeholders within the health care system from the high costs of prescription drug products. Contains provisions concerning Board membership and terms; staff for the Board; Board meetings; circumstances under which Board members must recuse themselves; and other matters. Provides that the Board shall perform the following actions in open session: (i) deliberations on whether to subject a prescription drug product to a cost review; and (ii) any vote on whether to impose an upper payment limit on purchases, payments, and payor reimbursements of prescription drug products in the State. Permits the Board to adopt rules to implement the Act and to enter into a contract with a qualified, independent third party for any service necessary to carry out the powers and duties of the Board. Creates the Health Care Availability and Access Stakeholder Council to provide stakeholder input to assist the Board in making decisions as required by the Act. Contains provisions concerning Council membership, member terms, and other matters. Provides that the Board shall adopt the federal Medicare Maximum Fair Price as the upper payment limit for a prescription drug product intended for use by individuals in the State. Prohibits the Board from creating an upper payment limit that is different from the Medicare Maximum Fair Price for the prescription drug product that has a Medicare Maximum Fair Price. Requires the Board to implement an upper payment limit that is the same as the Medicare Maximum Fair Price no sooner than the Medicare implementation date. Provides that Medicare Part C and D plans are not required to reimburse at the upper payment limit. Provides that the Attorney General may enforce the Act and may pursue any available remedy under State law when enforcing the Act. Effective 180 days after becoming law.

Actions 
DateChamber Action
  1/13/2025SenateFiled with Secretary by Sen. Robert Peters
  1/13/2025SenateFirst Reading
  1/13/2025SenateReferred to Assignments
  1/30/2025SenateAdded as Co-Sponsor Sen. Michael W. Halpin
  1/31/2025SenateAdded as Co-Sponsor Sen. Mary Edly-Allen
  2/3/2025SenateAdded as Co-Sponsor Sen. Rachel Ventura
  2/5/2025SenateAdded as Co-Sponsor Sen. Mike Porfirio
  2/5/2025SenateAdded as Chief Co-Sponsor Sen. David Koehler
  2/6/2025SenateAdded as Co-Sponsor Sen. Laura M. Murphy
  2/6/2025SenateAdded as Chief Co-Sponsor Sen. Mike Simmons
  2/6/2025SenateAdded as Chief Co-Sponsor Sen. Karina Villa
  2/25/2025SenateAdded as Chief Co-Sponsor Sen. Graciela Guzmán
  2/25/2025SenateAdded as Co-Sponsor Sen. Christopher Belt
  3/5/2025SenateAdded as Co-Sponsor Sen. Celina Villanueva
  3/19/2025SenateAdded as Co-Sponsor Sen. Mark L. Walker
  4/4/2025SenateAdded as Co-Sponsor Sen. Kimberly A. Lightford
  4/29/2025SenateAdded as Co-Sponsor Sen. Doris Turner

Back To Top